Compare Gigacloud Technology Inc (GCT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Incyte Corporation — how do they compare? Gigacloud Technology Inc trades at $52.01 (market cap $1.84B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 13.3× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| GCT | INCY | |
|---|---|---|
Market Cap | $1.84B | $24.54B |
Sector | Technology | Health |
52-Week High | $53.25 | $129.93 |
52-Week Low | $25.44 | $81.61 |
Enterprise Value | $1.97B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $51.66, up 0.02% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a 10.65% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, with consistent profitability.
The stock presents a compelling opportunity with attractive valuations (P/E 12.25, P/S 1.3) and robust fundamentals, though overbought RSI levels near 84 suggest near-term consolidation risk. Analyst consensus is bullish with 67% buy ratings, but investors should monitor execution risks in European expansion and furniture market volatility.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
